These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35293602)

  • 41. Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer.
    Pereira M; Matuszewska K; Jamieson C; Petrik J
    Front Endocrinol (Lausanne); 2021; 12():772349. PubMed ID: 34867818
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Critical appraisal of epigenetic regulation of galectins in cancer.
    Gadwal A; Modi A; Khokhar M; Vishnoi JR; Choudhary R; Elhence P; Banerjee M; Purohit P
    Int J Clin Oncol; 2022 Jan; 27(1):35-44. PubMed ID: 34652614
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Galectins in Esophageal Cancer: Current Knowledge and Future Perspectives.
    Godefa TM; Derks S; Thijssen VLJL
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497271
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression and functions of galectin-7 in ovarian cancer.
    Labrie M; Vladoiu MC; Grosset AA; Gaboury L; St-Pierre Y
    Oncotarget; 2014 Sep; 5(17):7705-21. PubMed ID: 25277199
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating galectins -2, -4 and -8 in cancer patients make important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasis.
    Chen C; Duckworth CA; Fu B; Pritchard DM; Rhodes JM; Yu LG
    Br J Cancer; 2014 Feb; 110(3):741-52. PubMed ID: 24384681
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sulfated sugars in the extracellular matrix orchestrate ovarian cancer development: 'when sweet turns sour'.
    Vallen MJ; van der Steen SC; van Tilborg AA; Massuger LF; van Kuppevelt TH
    Gynecol Oncol; 2014 Nov; 135(2):371-81. PubMed ID: 25158037
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Galectins as modulators of tumour progression.
    Liu FT; Rabinovich GA
    Nat Rev Cancer; 2005 Jan; 5(1):29-41. PubMed ID: 15630413
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
    Laderach DJ; Gentilini LD; Giribaldi L; Delgado VC; Nugnes L; Croci DO; Al Nakouzi N; Sacca P; Casas G; Mazza O; Shipp MA; Vazquez E; Chauchereau A; Kutok JL; Rodig SJ; Elola MT; Compagno D; Rabinovich GA
    Cancer Res; 2013 Jan; 73(1):86-96. PubMed ID: 23108139
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of galectins in colorectal cancer progression.
    Barrow H; Rhodes JM; Yu LG
    Int J Cancer; 2011 Jul; 129(1):1-8. PubMed ID: 21520033
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemokine receptors in epithelial ovarian cancer.
    Muralidhar GG; Barbolina MV
    Int J Mol Sci; 2013 Dec; 15(1):361-76. PubMed ID: 24384839
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vascular endothelial growth factor in ovarian cancer.
    Hazelton DA; Hamilton TC
    Curr Oncol Rep; 1999 Sep; 1(1):59-63. PubMed ID: 11122799
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Role of Galectins in Tumor Progression, Treatment and Prognosis of Gynecological Cancers.
    Chetry M; Thapa S; Hu X; Song Y; Zhang J; Zhu H; Zhu X
    J Cancer; 2018; 9(24):4742-4755. PubMed ID: 30588260
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New roles for galectins in brain tumors--from prognostic markers to therapeutic targets.
    Stillman BN; Mischel PS; Baum LG
    Brain Pathol; 2005 Apr; 15(2):124-32. PubMed ID: 15912884
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
    Saied EM; El-Etreby NM
    Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of Sox6 and Netrin-1 in ovarian cancer cell growth, invasiveness, and angiogenesis.
    Li Y; Xiao M; Guo F
    Tumour Biol; 2017 May; 39(5):1010428317705508. PubMed ID: 28475012
    [TBL] [Abstract][Full Text] [Related]  

  • 56. LncRNA DANCR promotes tumor growth and angiogenesis in ovarian cancer through direct targeting of miR-145.
    Lin X; Yang F; Qi X; Li Q; Wang D; Yi T; Yin R; Zhao X; Zhong X; Bian C
    Mol Carcinog; 2019 Dec; 58(12):2286-2296. PubMed ID: 31545000
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment.
    Au-Yeung CL; Yeung TL; Achreja A; Zhao H; Yip KP; Kwan SY; Onstad M; Sheng J; Zhu Y; Baluya DL; Co NN; Rynne-Vidal A; Schmandt R; Anderson ML; Lu KH; Wong STC; Nagrath D; Mok SC
    Nat Commun; 2020 Jul; 11(1):3546. PubMed ID: 32669559
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
    van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials.
    Compagno D; Tiraboschi C; Garcia JD; Rondón Y; Corapi E; Velazquez C; Laderach DJ
    Biomolecules; 2020 May; 10(5):. PubMed ID: 32408492
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Galectins as regulators of cell survival in the leukemia niche.
    Ruvolo PP
    Adv Biol Regul; 2019 Jan; 71():41-54. PubMed ID: 30245264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.